Casey Lynch, Cortexyme CEO
February 16, 2021 08:41 AM ESTUpdated February 17, 04:34 PM
FDA+

Up­dat­ed: Cor­texyme's un­ortho­dox Alzheimer's ap­proach tripped up by FDA hold

Jason Mast

Editor

The FDA has thrown a mi­nor wrench in Cor­texyme’s un­ortho­dox plan to treat Alzheimer’s.

On Mon­day, the Bay Area biotech an­nounced that the agency had …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Why did Eli Lil­ly ask a pa­tient on a com­pound­ed GLP-1 drug for their med­ical in­for­ma­tion?

FDA OKs the first-ever self-ad­min­is­tered vac­cine, for flu

The drug lob­by's law­suit against the IRA finds a sign of life af­ter ap­peals court rul­ing

Biotech VC firm out­lines plans for $100M fund

FTC to sue ma­jor PBMs over in­sulin re­bates, claim­ing they in­flat­ed pa­tient cost

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times